LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Maheswaran Kesavan"
  2. AU="Mehta, Mrunal"
  3. AU=Paredes Sergio D
  4. AU=Ghosh Nilanjan AU=Ghosh Nilanjan
  5. AU="Hofmann, Alexander"
  6. AU="Radici, Marco"
  7. AU="Noro, Fabrizia"
  8. AU="Wang, Jianzhao"
  9. AU="Divya Jeyam"
  10. AU="Wolf, Lisette"
  11. AU="Marjanovic, Nemanja Despot"
  12. AU="Jitxin, Lim"

Suchergebnis

Treffer 1 - 1 von insgesamt 1

Suchoptionen

Artikel ; Online: Hsp90 Inhibition

Suran Nethisinghe / Rosella Abeti / Maheswaran Kesavan / W. Christian Wigley / Paola Giunti

International Journal of Molecular Sciences, Vol 22, Iss 11722, p

A Promising Therapeutic Approach for ARSACS

2021  Band 11722

Abstract: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disease caused by mutations in the SACS gene, encoding the 520 kDa modular protein sacsin, which comprises multiple functional sequence domains that suggest a role ... ...

Abstract Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disease caused by mutations in the SACS gene, encoding the 520 kDa modular protein sacsin, which comprises multiple functional sequence domains that suggest a role either as a scaffold in protein folding or in proteostasis. Cells from patients with ARSACS display a distinct phenotype including altered organisation of the intermediate filament cytoskeleton and a hyperfused mitochondrial network where mitochondrial respiration is compromised. Here, we used vimentin bundling as a biomarker of sacsin function to test the therapeutic potential of Hsp90 inhibition with the C-terminal-domain-targeted compound KU-32, which has demonstrated mitochondrial activity. This study shows that ARSACS patient cells have significantly increased vimentin bundling compared to control, and this was also present in ARSACS carriers despite them being asymptomatic. We found that KU-32 treatment significantly reduced vimentin bundling in carrier and patient cells. We also found that cells from patients with ARSACS were unable to maintain mitochondrial membrane potential upon challenge with mitotoxins, and that the electron transport chain function was restored upon KU-32 treatment. Our preliminary findings presented here suggest that targeting the heat-shock response by Hsp90 inhibition alleviates vimentin bundling and may represent a promising area for the development of therapeutics for ARSACS.
Schlagwörter ARSACS ; ataxia ; vimentin ; KU-32 ; Hsp90 inhibition ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
Thema/Rubrik (Code) 570
Sprache Englisch
Erscheinungsdatum 2021-10-01T00:00:00Z
Verlag MDPI AG
Dokumenttyp Artikel ; Online
Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

Zusatzmaterialien

Kategorien

Zum Seitenanfang